Not buying the strength and scope of that letter. Someone
Not buying the strength and scope of that letter. Someone doesn’t know their facts when they allude that IncellDX is a publicly traded company and they are an investor. Making bold claims to have 175 million shares to be represented in their group. That... I don’t believe. Having control over 30% of the all traded shares...really? We didn’t fall off the turnip truck just yesterday. This letter is a spoof.
Dr. Patterson owns IncellDX outright and need no affiliation with Cytodyn to further his business. He is making kits that will be used the world over. He will be a wealthy man from his business with Covid and helping the world survive this pandemic.
I love Doctor Patterson as much as the next Cytodyn investor or maybe more. Dr. Patterson will do more research on Long Haulers with Leronlimab once we have an approval or EUA and it’s available for him to use. He has substituted another CCR5 antagonist to study currently because he wants to understand the connection. That drug has side effects and not such a good safety record as Leronlimab.
As a business or as people you learn to move on from our relationships when things don’t go as planned. This is where we are at. In our relationship with Dr. BP. It’s not a bad thing... he still talks well of Leronlimab and Nader and Cytodyn respect and only say good things about Dr. BP. We need to stop this nonsense about grasping at a time in our history of that relationship and just move forward without any further ideology that we need each other to promote our mutual direction in Covid.
Dr Patterson doesn’t need us and Cytodyn doesn’t need him either. We have a great sense of direction on where we want to progress indications that we have chosen to progress. We have qualified doctors giving advice and also directing our path as we progress. This nonsense of second guessing the leadership of this company needs to stop.
We are on a path to greatness in my opinion. If you don’t have the same opinion. You might want to sell your shares and move on. To post spoof letters like the one you posted from someone else is just plain nonsense. Nothing personal Dr Frank. I would expect more from an intelligent investor like yourself.
15
4
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A Legal Eagle Soars High in 2027 Oh, the legal world can be as cutthroat as the stock market some days, especially when you're gunning for those top-tier rankings. This year, McKinley Irvin has managed to ruffle a few feathers in the Pacific Northwest, claiming top honors in the 2027 Best Law Firms rankings. And let me tell you, this wasn’t just handed to them on a...
Continue Reading
Investing in Koppers: A Mixed Bag in Q3 Well, it appears Koppers (NYSE: KOP) is doing a bit of a dance this quarter—some smooth steps, but a few stumbles in the rhythm when it comes to margins. The hardwood numbers tell an interesting tale, so let's break it down. Sales Edge Up, But Margins Suffer Koppers clocked in net sales of $499.1 million for the third quarter of...
Continue Reading
Kickoff at Central Grove: What’s Brewing? Ever wander through Kearneysville, W.Va., and wonder what’s going on with that bustling crew near Goldenrod Drive? The folks at West Virginia American Water have kicked off groundwork for the much-anticipated Central Grove Water Treatment Plant. This, comrades, isn’t just some shiny new shed we’re talking about. Oh no,...
Continue Reading
Stepping into Soligenix's News Every time Soligenix pops up on the radar, it feels like we're watching a biopharma soap opera. This time, they're juggling updates and quarterly numbers that scream both promise and peril. The New Jersey-based company, known for its focus on niche markets with unmet medical needs, tossed out some shiny clinical developments alongside a...
Continue Reading
Revolutionizing Access: Pharmaceuticals Meet Telehealth In an era where digital disruption is shaking every sector, Eli Lilly (NYSE:LLY) isn't sitting idle. They've just forged a partnership with Hims & Hers (NYSE:HIMS), one that's diving headfirst into the telehealth revolution. We're talking a slick merger of pharmaceuticals and digital platforms—offering FDA-approved...
Continue Reading
Legal Storms Gather on Pinterest's Horizon I remember a time when Pinterest was the darling of Wall Street, but here we are, staring at an investigation that's got more layers than an onion. On November 6, 2026, news broke that Kahn Swick & Foti, LLC (KSF) is sniffing around Pinterest's officers and directors. This is no small fry since KSF is steered by none other than...
Continue Reading
CorelDRAW: A Design Powerhouse Without Recurring Bills? Every so often, a software option comes along that piques my interest, and right now, it's CorelDRAW Graphics Suite. Consumer365 has shone a light on this nifty tool for its one-time purchase model—a breath of fresh air in the age of endless subscriptions that seem to drain more than enthusiasm as the months roll...
Continue Reading
The Storm Brewing Over Madrigal Pharmaceuticals Well, folks, here we are smack dab in the middle of another roller-coaster ride in the biotech sector, and it ain't pretty. Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is in hot water with some serious allegations thrown their way. The company is now under investigation by Kessler Topaz Meltzer & Check, LLP, a top-notch...
Continue Reading
NovoTech's Moment in the Spotlight Every once in a while, a small fish manages to swim with the sharks and come out shining. NovoTech, a relative newcomer in the swarm of patent law firms, has snagged itself a spot in the inaugural Chambers USA Spotlight 2027 DC Metro Guide. Considering they're playing in the bustling intellectual property scene, this is no small...
Continue Reading
Innodisk's Skyrocketing Financial Surge Imagine raking in a revenue leap of 579.9% year-over-year. Yep, that's what Innodisk—a major player from Taiwan in industrial memory, storage, and edge AI solutions—just reported for Q3. I'll go out on a limb here and say that doesn't happen every day. Key Numbers That Paint the Big Picture Let’s dive into those digits. We're...
Continue Reading
Top 5 Most Recently Viewed Articles
W3.io Secures Funding to Transform Web3 Landscape Web3 has limitless potential, yet its adoption has faced significant barriers. The fragmented and complex infrastructure proved to be a challenge, leading to a bottleneck in usability. This reality is what prompted W3.io to take a proactive stance. W3.io, spearheaded by a groundbreaking coalition of innovators,...
Continue Reading
Democratizing Private Investing with Linqto Linqto, a pioneer in financial technology, is reshaping the landscape of private investing. They are committed to making investments in private companies and startups accessible to individual investors, enabling them to tap into opportunities traditionally reserved for institutional players. The company continually enhances its...
Continue Reading
Flux Power Appoints New Leadership for Growth Flux Power Holdings, Inc. (NASDAQ: FLUX), a key player in advanced lithium-ion energy storage solutions, has made a significant step towards future growth by appointing Kelly Frey as the Chief Revenue Officer. This strategic move follows the announcement of Tod Kilgore's retirement, effective at the end of January 2025. Mr....
Continue Reading
Ecopetrol's Strategic Acquisition of Repsol's Stake Ecopetrol S.A. (EC), a leading energy company in the region, has announced an agreement with Repsol to purchase their 45% stake in the Exploration and Production Contract for Block CPO-09. This acquisition represents a significant milestone for Ecopetrol, reinforcing its position as a dominant player in the energy...
Continue Reading
ACTEC Expands Its Fellowship with 51 New Members In a momentous decision during a recent meeting, The American College of Trust and Estate Counsel (ACTEC) proudly welcomed 51 new individuals into its prestigious fellowship. The organization, renowned for its commitment to excellence in trust and estate law, highlighted the election of 48 new Fellows, one Academic Fellow,...
Continue Reading